



(51) International Patent Classification:

A61K 31/404 (2006.01) A61K 31/47 (2006.01)

A61K 45/06 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2019/061171

(22) International Filing Date:

13 November 2019 (13.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/767,202 14 November 2018 (14.11.2018) US

(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: **ALTSHULER, David M.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **ANDERSON, Corey Don**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CHEN, Weichao George**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CLEMENS, Jeremy J.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CLEVELAND, Thomas**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **COON, Timothy Richard**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **FRIEMAN, Bryan**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **GROOTENHUIS, Peter** (deceased). **HADIDA RUAH, Sara Sabina**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **HARE, Brian J.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **KEWALRAMANI, Reshma**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **MCCARTNEY, Jason**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **MILLER, Mark Thomas**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **PARASEL-LI, Prasuna**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **PIERRE, Fabrice**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **ROBERTSON, Sarah M.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **SOSNAY, Patrick R.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **SWIFT, Sara E.**; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

ZHOU, Jinglan; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: **MCDONELL, Leslie A.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS OF TREATMENT FOR CYSTIC FIBROSIS



(I)

(57) Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

